On August 9, 2024, the NRC issued an Information Notice to inform licensees of recent reported medical events that involved the administration of therapeutic radiopharmaceuticals and does not impose new requirements or need for action. The NRC expects that recipients will review the information for applicability to their facilities and consider actions, as appropriate. In accordance with 10 CFR 35.41, “Procedures for administrations requiring a written directive,” licensees are required to develop, implement and maintain written procedures to provide high confidence that each administration is in accordance with the written directive for any therapeutic radiopharmaceutical administration. When licensees are considering adding new treatment protocols to their clinic, they should update the procedures to ensure that the new therapeutic radiopharmaceuticals can be administered in accordance with the written directive. Licensees are encouraged to consider the medical events experience provided in the Information Notice in the development of these procedures.